Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$576K Sell
3,930
-10
-0.3% -$1.81K 0.02% 256
2026
Q1
$580K Buy
3,940
+425
+12% +$69.1K 0.03% 242
2025
Q4
$685K Sell
3,515
-59
-2% -$14K 0.03% 219
2025
Q3
$1.01M Sell
3,574
-946
-21% -$241K 0.05% 185
2025
Q2
$988K Sell
4,520
-28
-0.6% -$4.52K 0.05% 179
2025
Q1
$636K Buy
4,548
+104
+2% +$16.9K 0.03% 202
2024
Q4
$741K Buy
4,444
+48
+1% +$8.53K 0.04% 191
2024
Q3
$749K Buy
4,396
+22
+0.5% +$3.19K 0.04% 192
2024
Q2
$618K Buy
4,374
+2,409
+123% +$299K 0.03% 203
2024
Q1
$247K Buy
+1,965
New +$225K 0.01% 272
2018
Q4
Sell
-592
Closed -$31K 438
2018
Q3
$31K Buy
592
+1
+0.2% +$49 ﹤0.01% 234
2018
Q2
$26K Buy
591
+452
+325% +$20.8K ﹤0.01% 235
2018
Q1
$6K Buy
+139
New +$6.91K ﹤0.01% 300

Other funds holding ORCL

Trilogy Capital's ORCL Position: Q2 2026 in Review

Trilogy Capital reduced its Oracle (ORCL) stake by 0.25% in Q2 2026, selling an estimated $1.81K and leaving 3,930 shares worth $576K. The position accounts for 0.02% of the portfolio, ranked #256.

Trilogy Capital first reported a position in ORCL in Q1 2018 and has held it in 13 quarters since. The position peaked at $1.01M in Q3 2025. 1,681 funds tracked by Wall St. Rank hold ORCL as of Q2 2026.

  • Trilogy Capital held 3,930 shares of Oracle worth $576K as of Q2 2026.
  • Trilogy Capital sold 10 Oracle shares in Q2 2026, an estimated $1.81K.
  • Oracle made up 0.02% of Trilogy Capital's portfolio in Q2 2026, its #256 holding.
  • Trilogy Capital first reported a position in Oracle in Q1 2018 and has held it in 13 quarters since.
  • Trilogy Capital's Oracle position peaked at $1.01M in Q3 2025.
  • 1,681 funds tracked by Wall St. Rank held Oracle as of Q2 2026.

Based on Trilogy Capital's 13F filing for Q2 2026, filed 6 Jul 2026.